Summary box
Achieving the United Nations Programme on HIV/AIDS (UNAIDS) 90–90–90 targets will
require a viral load-informed care to ensure optimal HIV clinical follow-up and resistance
monitoring—this in turn will require significant mobilisation of resources.
Maintaining a constant drug supply to satisfy the growing number of potential patients
to be put on treatment with current funding trends is almost unattainable.
Poor quality and non-uniform data collection tools of the various indicators render
evaluation of the evolution of the HIV pandemic extremely difficult.
The UNAIDS 90–90–90 agenda is non-inclusive, disease specific and might contribute
to weakening health systems which are already challenged by the double burden of communicable
and non-communicable diseases.
There is indisputable evidence regarding the remarkable success over the past two
decades in reducing HIV associated morbidity, mortality, transmission, stigma and
improving the quality of life of people living with HIV.1 In 2014, the Joint United
Nations Programme on HIV/AIDS (UNAIDS) and partners launched the 90–90–90 targets;
the aim was to diagnose 90% of all HIV-positive persons, provide antiretroviral therapy
(ART) for 90% of those diagnosed, and achieve viral suppression for 90% of those treated
by 2020. This is estimated to result in 73% of people with HIV achieving viral suppression,
a crucial step in ending the AIDS epidemic by 2030.2 However, 36.9 million people
are living with HIV today and about 2.1 million new infections were recorded in 2015.3
This high rate of new infections continues to fuel the epidemic. Reports from national
HIV programmes suggest that the 90–90–90 targets agenda for 2020 risks are unrealistic.4
Early placement of patients on combined ART (cART) and achievement of viral load suppression
reduces mortality and HIV transmission and improves quality of life.1 Getting over
90% of people with HIV to know their status can therefore plausibly help achieve the
90–90–90 targets. However, in a recent systematic analysis of national HIV treatment
cascades from 69 countries by Levi et al
4 in BMJ Global Health, none of the countries had met the 90–90–90 targets. They found
that diagnosis (target one—90% of all HIV-positive people diagnosed) ranged from 87%
(the Netherlands) to 11% (Yemen). Treatment coverage (target two—81% of all HIV-positive
people on ART) ranged from 71% (Switzerland) to 3% (Afghanistan). Viral suppression
(target three—73% of all HIV-positive people virally suppressed) was between 68% (Switzerland)
and 7% (China). In 2014/2015, of the 36.9 million of people with HIV globally, only
54% were diagnosed, 41% were on ART and 32% were virally suppressed, demonstrating
that we are still very far from achieving the 90–90–90 targets. The lowest achievement
rates were in low income and middle income countries (LMICs).
Levi et al
4 adequately highlighted the gaps in HIV diagnosis and provision of cART, which may
be unattainable under the ambitious UNAIDS 90–90–90 targets given the current trends.
However, the targets only make sense if HIV testing is performed under acceptable
conditions and appropriate interventions to ensure linkage to care after testing are
put in place. Improving the quality of counselling could ameliorate linkage to care,
trust and compliance.5 It is no news that social workers and trained psychosocial
support staff remain scarce if not inexistent in most healthcare facilities that manage
patients with HIV. Without refuting the fact that HIV-associated stigma has reduced
significantly worldwide, it still constitutes a hindrance to optimal care, even in
developed countries.6–8
Putting adequate and holistic interventions in place requires good data. Levi et al
4 identified lack of good quality data, as well as its non-uniformity, which renders
cross-national comparisons difficult. Of the 196 eligible countries, they only found
available data on 69 countries for analysis. Paediatric HIV care remains a core hindrance
to achieving the 90–90–90 targets. With unacceptably high numbers of HIV-infected
children who are not on treatment9 and potential new HIV-infected patients who will
be diagnosed and consequently deserve treatment with expanded screening, it is questionable
if health systems will be able to meet the demand for and ensure the continuous supply
of cART.4 Periodic unavailability of drugs is a key driver of drug resistance. Resistance
to first-line therapy is already here, and could get worse if immediate and appropriate
action is not taken.10
11
Early detection of treatment failure, adherence counselling and appropriate switching
to second-line therapy are key strengths of a viral load monitored model.11 Investing
and ensuring the sustainability of a viral load-informed care and monitoring model10
11 must be a priority. This, of course, shall involve mobilisation of resources. Unfortunately,
global health challenges go far beyond HIV, and many other leading causes of death
and disability also deserve increased attention. Priority setting and health system
reforms to manage HIV as a chronic disease must be upheld in government agendas of
LMICs.
Indeed, non-communicable diseases (NCDs) are set to overtake HIV and other infectious
diseases as the top killers in low-income countries (LICs) by 2030. These countries
are still ill-prepared to cope with the rising epidemic of cardiovascular diseases
(CVDs) and NCDs in general.12 Despite the increasing burden of diabetes mellitus and
CVDs in the HIV population, even HIV clinics in these settings are unprepared for
the diagnosis and management of NCDs in the context of HIV care.13 Considering the
already huge and increasing burden on health systems of diseases other than HIV, inclusive
approaches are needed to provide integrated care for both infectious diseases and
NCDs to populations at the primary healthcare level. A disease-specific agenda focusing
on HIV is therefore self-destructive. Moreover, meeting the future resource needs
for ART scale-up under the 90–90–90 scenario (US$18 billion per year globally) will
require significant additional resource mobilisation, which may jeopardise funding
of other health programmes. Large gaps exist across countries with respect to meeting
targets, with highly affected and LIC lagging behind.4
Indeed, before ending the HIV epidemic by 2030, the 90–90–90 strategy would have significantly
weakened health systems and impeded the fight against the rising NCDs burden in LICs.
Active research and development of community friendly interventions are highly needed.14
This can lead to an increase in screening rates; also, early identification of patients
lost to follow-up and addressing of special psychosocial concerns could be achieved.14
Getting good and uniform data constitutes a priority to better monitor, plan and act
appropriately within the context of evolving towards meeting these, for the moment
elusive targets, especially in LMICs.4 Although Levi et al
4 did not explore linkage to care and retention in their systematic analysis, they
highlighted the fact that placement of diagnosed persons on ART shall constitute a
key barrier to attaining the 90–90–90 targets in most LMICs. However, political will,
appropriate planning and obtaining required funds could be game changers towards reaching
these goals.